/

GUD.TO

KNIGHT THERAPEUTICS INCClosed

10.61−0.07 −0.66%CAD

Toronto · as of Oct 14, 16:00 ET · 15m delay

Open

10.65

Prev close

10.68

Day range

10.5910.73

52-week range

5.6611.00

Volume

66.53K0.80×

Mkt cap

1.04B

P/E ttm

70.73

Fwd P/E

40.81

EPS ttm

0.1500

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−3.55%

Price Chart

Yahoo Finance · delayed

GUD.TOOct 14, 2026O 10.65H 10.73L 10.59C 10.61−0.07 (−0.66%)Vol 66.53K

SMA 509.96
SMA 2008.20

1Y change +83.88% since Oct 10, 2025 close540 bars loadedTimes in America/TorontoDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

GUD.TO KNIGHT THERAPEUTICS INC · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.93%
1 month: +5.89%
3 months: +9.16%
6 months: +37.08%
Year to date: +75.37%
1 year: +84.52%

Valuation & ownership

Market cap: 1.04B
Enterprise value: 962.22M
P/E (ttm): 70.73
Forward P/E: 40.81
PEG ratio: —
Price / book: 1.31
Price / sales (ttm): 1.90
EV / EBITDA: 11.86
EPS (ttm): 0.1500
EPS (forward): 0.2600
Beta (5y monthly): -0.01
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 98.23M
Float: 60.60M
Short % of float: —
Short ratio (days): 13.51
Held by insiders: 46.02%
Held by institutions: 19.05%
Avg volume (3m): 83.08K
50-day average: 9.94
200-day average: 8.18
52-week change: +84.52%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 59.5
vs 50-day SMA: +6.57%
vs 200-day SMA: +29.41%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 2.51%
Realised vol (20d, ann.): 22.0%
From 52-week high: −3.55%
From 52-week low: +87.46%

ANR

Analyst Consensus

7 analysts

Consensus

—

Mean target

11.19

+5.43% implied

Low 10.80Median 11.00High 12.00

Recommendation trend

Now7 / 0 / 0
1m ago7 / 0 / 0

Buy / hold / sell counts

DES

About KNIGHT THERAPEUTICS INC

Yahoo Finance profile

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 830
Headquarters

SEAS

Seasonality · GUD.TO

2014–2026 · monthly returns

Strongest month Apr +3.32%Weakest month Mar −2.03%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.1	8.3	18.0	1.2	9.2	20.3	-0.1	-1.8	9.6	0.2			+75.4%
2025	3.7	-0.9	12.0	-1.1	-5.3	1.2	4.5	6.7	-9.5	-0.7	3.6	0.0	+13.3%
2024	2.3	2.4	-2.6	8.9	4.0	-5.5	0.9	-4.0	8.0	-4.9	-6.6	1.3	+2.9%
2023	-1.2	-0.4	-13.7	2.3	6.7	2.9	-2.2	-5.4	-1.5	1.1	13.2	0.8	+0.2%
2022	4.7	-2.0	-4.0	2.1	2.4	-2.2	8.4	-1.6	-6.8	4.5	-2.7	-4.1	−2.3%
2021	-1.1	-2.5	5.2	-0.6	-1.7	-1.1	-2.5	4.9	-0.4	-3.9	2.5	0.6	−0.9%
2020	3.6	-15.0	-7.0	22.4	0.3	-7.8	-1.4	-10.3	-6.6	-5.7	0.7	-2.9	−29.4%
2019	2.5	-2.9	-4.1	-0.5	3.3	2.4	-3.0	0.5	-1.3	12.8	-6.9	-2.8	−1.4%
2018	-8.5	2.0	0.0	1.4	2.3	0.1	6.2	1.1	-4.9	-4.4	8.8	-10.1	−7.5%
2017	-4.3	4.3	-3.1	2.1	-5.6	2.7	-7.8	-10.6	2.0	-3.1	-7.2	6.8	−22.6%
2016	-12.3	10.5	5.6	2.4	3.0	-0.4	2.3	3.2	8.2	-5.9	15.8	4.0	+39.1%
2015	17.2	12.9	-10.7	-9.5	-10.4	1.1	11.2	-5.4	0.1	10.3	-0.1	-0.8	+11.6%
2014				10.0	-2.8	-4.4	-5.0	6.6	12.2	-5.2	17.4	1.3	+31.1%

INSD

Insider Activity · GUD.TO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 14, 2026	Emblem (Susan Caroline)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 7.09 per share.	714	$5.06K
Sep 14, 2026	Emblem (Susan Caroline)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 4.05 per share.	292	$1.18K
Sep 14, 2026	Goodman (Jonathan Ross)Director of Issuer	Acquisition under a purchase/ownership plan at price 7.09 per share.	587	$4.16K
Sep 14, 2026	Goodman (Jonathan Ross)Director of Issuer	Acquisition under a purchase/ownership plan at price 4.05 per share.	223	$902
Sep 14, 2026	Khouri, AmalSenior Officer of Issuer	Acquisition under a purchase/ownership plan at price 7.09 per share.	633	$4.49K
Sep 14, 2026	Khouri, AmalSenior Officer of Issuer	Acquisition under a purchase/ownership plan at price 4.05 per share.	506	$2.05K
Sep 14, 2026	Lopez (German)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 7.09 per share.	722	$5.12K
Sep 14, 2026	Lopez (German)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 4.05 per share.	186	$752
Sep 14, 2026	Sakhia, SamiraDirector of Issuer	Acquisition under a purchase/ownership plan at price 7.09 per share.	1.6K	$11.21K
Sep 14, 2026	Sakhia, SamiraDirector of Issuer	Acquisition under a purchase/ownership plan at price 4.05 per share.	600	$2.43K
Sep 14, 2026	Utchanah (Arvind)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 7.09 per share.	686	$4.87K
Sep 14, 2026	Utchanah (Arvind)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 4.05 per share.	274	$1.11K
Jul 12, 2026	Utchanah (Arvind)Senior Officer of Issuer	Exercise of options at price 5.48 per share.	8.1K	$44.16K
Jun 14, 2026	Dos Santos Dias (Henrique Jose)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 3.73 per share.	140	$522
Jun 14, 2026	Emblem (Susan Caroline)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 6.69 per share.	876	$5.86K
Jun 14, 2026	Emblem (Susan Caroline)Senior Officer of Issuer	Acquisition under a purchase/ownership plan at price 3.73 per share.	361	$1.35K
Jun 14, 2026	Goodman (Jonathan Ross)Director of Issuer	Acquisition under a purchase/ownership plan at price 6.69 per share.	718	$4.80K
Jun 14, 2026	Goodman (Jonathan Ross)Director of Issuer	Acquisition under a purchase/ownership plan at price 3.73 per share.	267	$996
Jun 14, 2026	Khouri, AmalSenior Officer of Issuer	Acquisition under a purchase/ownership plan at price 6.69 per share.	774	$5.18K
Jun 14, 2026	Khouri, AmalSenior Officer of Issuer	Acquisition under a purchase/ownership plan at price 3.73 per share.	593	$2.21K

GUD.TO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

GUD.TO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About KNIGHT THERAPEUTICS INC

Seasonality · GUD.TO

Insider Activity · GUD.TO

Congress Trades · GUD.TO

Investors Holding GUD.TO

Investors Holding GUD.TO

Congress Trades · GUD.TO

Insider Activity · GUD.TO

Seasonality · GUD.TO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About KNIGHT THERAPEUTICS INC

Financial Snapshot

Earnings & Dividends

News